Story detail
Read the key details here, then continue on the original publisher.
Today's biotech news features the FDA weighing the fate of peptides; approvals for RevMed, GSK; and data on Lilly's "triple-G."
Join our channel to receive the latest headlines and breaking stories as soon as they are published.
Scientists discovered that damaged fat cells can become inflamed, lose their ability to store lipids, and eventually vanish, disrupting the body’s metabolism. The findings show that diabetes can result not only from excess fat, but also from losing the healthy fat tissue the body needs.
These specialized units can help keep older patients out of the hospital, lower their health care costs and more.
The voluntary recall included eggs produced in Texas and sold under several brand names in six states, the Food and Drug Administration said.
The committee endorsed broader use of the peptides in lightly regulated compounding pharmacies that have grown into a multibillion-dollar business.
The agency is considering whether compounding pharmacies should be allowed to produce BPC-157, TB-500 and other previously banned peptides.
“Consumers should not be faced with a trade-off between nutrition and food safety,” writes Susan Mayne, former director of the FDA Center for Food Safety and Applied Nutrition.
Comments (0)
Join the conversation. Comments are rate-limited, secured, and GDPR-compliant.
No comments yet. Be the first to share your thoughts!